We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Commercial Availability of Lutetium-177

By Biotechdaily staff writers
Posted on 06 Nov 2002
Print article
Lutetium-177 (Lu-177), an important radioisotope being investigated for use in the radiotherapeutic treatment of cancers such as breast, prostate, colon and brain, is now commercially available from PerkinElmer Life Sciences (Boston, MA, USA).

PerkinElmer says it is the first company with worldwide distribution capabilities to offer Lu-177. Until now, there has been no reliable supplier of this important radioisotope. Demand for Lu-177 is increasing, and the current commercial supply is limited. PerkinElmer's goal is to provide the market with a much-needed continuous and reliable supply. The company's broad distribution channels are geared to help ensure timely, quality delivery of this short-lived isotope. The product is available for research use only.

PerkinElmer is committed to accelerating the market development for this important radioisotope, which could lead to another treatment for cancer,” said Paul Gillyon, vice president and general manager of research products at PerkinElmer Life Sciences. "By making radionuclides like lutetium-177 and yttrium-90 available commercially, we believe we can support and impact research that will lead to newer and better therapeutic alternatives.”




Related Links:
PerkinElmer
Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: A one-step confirmatory laboratory test could definitively diagnose active syphilis infection within 10 minutes (Photo courtesy of Adobe Stock)

First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes

In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more

Molecular Diagnostics

view channel
Image: Proposed mechanism of action of miR-126-3p in knee OA (Photo courtesy of Nature Communications/DOI: 10.1038/s41467-025-57308-5)

Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis

The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more